114 related articles for article (PubMed ID: 12517502)
1. Edrecolomab in the adjuvant treatment of colorectal carcinoma.
Spizzo G; Obrist P; Went P; Dirnhofer S; Gastl G
Lancet; 2003 Jan; 361(9351):83; author reply 83. PubMed ID: 12517502
[No Abstract] [Full Text] [Related]
2. Edrecolomab in the adjuvant treatment of colorectal carcinoma.
Alliot C
Lancet; 2003 Jan; 361(9351):82; author reply 83. PubMed ID: 12517501
[No Abstract] [Full Text] [Related]
3. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.
Schwartzberg LS
Crit Rev Oncol Hematol; 2001 Oct; 40(1):17-24. PubMed ID: 11578913
[TBL] [Abstract][Full Text] [Related]
4. When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab.
Schmoll HJ; Arnold D
J Clin Oncol; 2009 Apr; 27(12):1926-9. PubMed ID: 19273695
[No Abstract] [Full Text] [Related]
5. Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer.
Gambill BD
Clin Colorectal Cancer; 2001 May; 1(1):16-7. PubMed ID: 12445374
[No Abstract] [Full Text] [Related]
6. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Punt CJ; Nagy A; Douillard JY; Figer A; Skovsgaard T; Monson J; Barone C; Fountzilas G; Riess H; Moylan E; Jones D; Dethling J; Colman J; Coward L; MacGregor S
Lancet; 2002 Aug; 360(9334):671-7. PubMed ID: 12241873
[TBL] [Abstract][Full Text] [Related]
7. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Naundorf S; Preithner S; Mayer P; Lippold S; Wolf A; Hanakam F; Fichtner I; Kufer P; Raum T; Riethmüller G; Baeuerle PA; Dreier T
Int J Cancer; 2002 Jul; 100(1):101-10. PubMed ID: 12115595
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: edrecolomab, Centocor Inc.
Abicht A; Lochmüller H
Curr Opin Mol Ther; 2000 Oct; 2(5):593-600. PubMed ID: 11249762
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy.
Goldberg RM
Onkologie; 2005 Jun; 28(6-7):311-2. PubMed ID: 15933417
[No Abstract] [Full Text] [Related]
11. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.
Chibaudel B; Tournigand C; André T; Larsen AK; de Gramont A
Clin Colorectal Cancer; 2010 Dec; 9(5):269-73. PubMed ID: 21208840
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer.
Fiedler W; Krüger W; Laack E; Mende T; Vohwinkel G; Hossfeld DK
Oncol Rep; 2001; 8(2):225-31. PubMed ID: 11182031
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab (Avastin).
Middleton G; Lapka DV
Clin J Oncol Nurs; 2004 Dec; 8(6):666-9. PubMed ID: 15637962
[No Abstract] [Full Text] [Related]
15. Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.
Graziano F; Catalano V; Baldelli AM; Cascinu S
Expert Rev Anticancer Ther; 2001 Aug; 1(2):247-57. PubMed ID: 12113030
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure.
Baptistella AR; Salles Dias MV; Aguiar S; Begnami MD; Martins VR
Anticancer Drugs; 2016 Sep; 27(8):734-7. PubMed ID: 27272411
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in colorectal cancer.
Wadler S
Clin Colorectal Cancer; 2007 Jan; 6(5):357-61. PubMed ID: 17311700
[TBL] [Abstract][Full Text] [Related]
18. Erbitux diagnostic latest adjunct to cancer therapy.
Mitchell P
Nat Biotechnol; 2004 Apr; 22(4):363-4. PubMed ID: 15060535
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies in the treatment of colorectal cancer.
Veronese ML; O'Dwyer PJ
Eur J Cancer; 2004 Jun; 40(9):1292-301. PubMed ID: 15177487
[TBL] [Abstract][Full Text] [Related]
20. [Oncology 2010].
Wörmann B
Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1339-40. PubMed ID: 20556695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
